Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 6 , Pages 1047-1059 , December 2008

The value of positron emission tomography (PET) in the management of patients with thyroid cancer

  • Richard J. Robbins, MD (Professor of Medicine, Weill Cornell Medical College; Chairman, Department of Medicine)

      Affiliations

    • Corresponding Author InformationCorresponding author.
  • Steven M. Larson, MD (Professor of Radiology, Weill Cornell Medical College; Chief, Nuclear Medicine Service)

References 

  1. Warburg O, Wind F, Neglers E. On the metabolism of tumors in the body. In:  Warburg O editors. Metabolism of tumors. London: Constable; 1930;p. 254–270
  2. Hatanaka M. Transport of sugars in tumor cell membranes. Biochimica et Biophysica Acta. 1974;355(1):77–104
  3. Weber G. Enzymology of cancer cells (second of two parts). The New England Journal of Medicine. 1977;296(10):541–551
  4. Sokoloff L, Reivich M, Kennedy C, et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. Journal of Neurochemistry. 1977;28(5):897–916
  5. Reivich M, Alavi A, Wolf A, et al. Glucose metabolic rate kinetic model parameter determination in humans: the lumped constants and rate constants for [18F]fluorodeoxyglucose and [11C]deoxyglucose. Journal of Cerebral Blood Flow and Metabolism. 1985;5(2):179–192
  6. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. Journal of Nuclear Medicine. 1987;28(5):910–914
  7. Feine U, Lietzenmayer R, Hanke JP, et al. 18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I, Nuklearmedizin. 1995;34(4):127–134
  8. Feine U, Lietzenmayer R, Hanke JP, et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. Journal of Nuclear Medicine. 1996;37(9):1468–1472
  9. Grunwald F, Schomburg A, Bender H, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. European Journal of Nuclear Medicine. 1996;23(3):312–319
  10. Scott GC, Meier DA, Dickinson CZ. Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG, technetium-99m-pertechnetate and iodine-131-sodium iodide. Journal of Nuclear Medicine. 1995;36(10):1843–1845
  11. Grunwald F, Menzel C, Bender H, et al. Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid. 1997;7(3):327–335
  12. Dietlein M, Scheidhauer K, Voth E, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. European Journal of Nuclear Medicine. 1997;24(11):1342–1348
  13. Altenvoerde G, Lerch H, Kuwert T, et al. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans. Langenbeck's Archives of Surgery. 1998;383(2):160–163
  14. Huang TS, Chieng PU, Chang CC, et al. Positron emission tomography for detecting iodine-131 nonvisualized metastasis of well-differentiated thyroid carcinoma: two case reports. Journal of Endocrinological Investigation. 1998;21(6):392–398
  15. Jadvar H, McDougall IR, Segall GM. Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography. Nuclear Medicine Communications. 1998;19(6):547–554
  16. Chung JK, So Y, Lee JS, et al. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. Journal of Nuclear Medicine. 1999;40(6):986–992
  17. Alnafisi NS, Driedger AA, Coates G, et al. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. Journal of Nuclear Medicine. 2000;41(6):1010–1015
  18. Wang W, Macapinlac H, Larson SM, et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. The Journal of Clinical Endocrinology and Metabolism. 1999;84(7):2291–2302
  19. Lind P, Kresnik E, Kumnig G, et al. 18F-FDG-PET in the follow-up of thyroid cancer. Acta Medica Austriaca. 2003;30(1):17–21
  20. Larson SM, Robbins R. Positron emission tomography in thyroid cancer management. Seminars in Roentgenology. 2002;37(2):169–174
  21. Hooft L, Hoekstra OS, Deville W, et al. Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. 2001;86(8):3779–3786
  22. Davison JM, Stocker DJ, Montilla-Soler JL, et al. The added benefit of a dedicated neck F-18 FDG PET-CT imaging protocol in patients with suspected recurrent differentiated thyroid carcinoma. Clinical Nuclear Medicine. 2008;33(7):464–468
  23. Stojadinovic A, Hoos A, Ghossein RA, et al. Hurthle cell carcinoma: a 60-year experience. Annals of Surgical Oncology. 2002;9(2):197–203
  24. Plotkin M, Hautzel H, Krause BJ, et al. Implication of 2-18fluor-2-deoxyglucose positron emission tomography in the follow-up of Hurthle cell thyroid cancer. Thyroid. 2002;12(2):155–161
  25. Lowe VJ, Mullan BP, Hay ID, et al. 18F-FDG PET of patients with Hurthle cell carcinoma. Journal of Nuclear Medicine. 2003;44(9):1402–1406
  26. Pryma DA, Schoder H, Gonen M, et al. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hurthle cell thyroid cancer patients. Journal of Nuclear Medicine. 2006;47(8):1260–1266
  27. Adler LP, Bloom AD. Positron emission tomography of thyroid masses. Thyroid. 1993;3(3):195–200
  28. Bloom AD, Adler LP, Shuck JM. Determination of malignancy of thyroid nodules with positron emission tomography. Surgery. 1993;114(4):728–734[discussion: 734–725]
  29. Uematsu H, Sadato N, Ohtsubo T, et al. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors. Journal of Nuclear Medicine. 1998;39(3):453–459
  30. Smith RB, Robinson RA, Hoffman HT, et al. Preoperative FDG-PET imaging to assess the malignant potential of follicular neoplasms of the thyroid. Otolaryngology Head and Neck Surgery. 2008;138(1):101–106
  31. Cohen MS, Arslan N, Dehdashti F, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery. 2001;130(6):941–946
  32. Van den Bruel A, Maes A, De Potter T, et al. Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma. The Journal of Clinical Endocrinology and Metabolism. 2002;87(4):1517–1520
  33. Davis PW, Perrier ND, Adler L, et al. Incidental thyroid carcinoma identified by positron emission tomography scanning obtained for metastatic evaluation. American Surgeon. 2001;67(6):582–584
  34. Katz SC, Shaha A. PET-associated incidental neoplasms of the thyroid. Journal of the American College of Surgeons. 2008;207(2):259–264
  35. Zoller M, Kohlfuerst S, Igerc I, et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality?. European Journal of Nuclear Medicine and Molecular Imaging. 2007;34(4):487–495
  36. Freudenberg LS, Frilling A, Kuhl H, et al. Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer. European Radiology. 2007;17(12):3139–3147
  37. Leboulleux S, Schroeder PR, Schlumberger M, et al. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nature Clinical Practice Endocrinology & Metabolism. 2007;3(2):112–121
  38. Seiboth L, Van Nostrand D, Wartofsky L, et al. Utility of PET/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer. Thyroid. 2008;18(2):103–111
  39. Sisson JC, Ackermann RJ, Meyer MA, et al. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. The Journal of Clinical Endocrinology and Metabolism. 1993;77(4):1090–1094
  40. Hosaka Y, Tawata M, Kurihara A, et al. The regulation of two distinct glucose transporter (GLUT1 and GLUT4) gene expressions in cultured rat thyroid cells by thyrotropin. Endocrinology. 1992;131(1):159–165
  41. van Tol KM, Jager PL, Piers DA, et al. Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid. 2002;12(5):381–387
  42. Moog F, Linke R, Manthey N, et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. Journal of Nuclear Medicine. 2000;41(12):1989–1995
  43. Petrich T, Borner AR, Otto D, et al. Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 2002;29(5):641–647
  44. Iagaru A, Kalinyak JE, McDougall IR. F-18 FDG PET/CT in the management of thyroid cancer. Clinical Nuclear Medicine. 2007;32(9):690–695
  45. Hoie J, Stenwig A, Kullmann G, et al. Distant metastases in papillary thyroid cancer. A review of 91 patients. Cancer. 1988;61:1–6
  46. Schlumberger M. Papillary and follicular thyroid carcinoma. The New England Journal of Medicine. 1998;338:297–306
  47. Rivera M, Ghossein RA, Schoder H, et al. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer. 2008;113(1):48–56
  48. Wang W, Larson SM, Fazzari M, et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. 2000;85(3):1107–1113
  49. Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. The Journal of Clinical Endocrinology and Metabolism. 2006;91(2):498–505
  50. Wang W, Larson SM, Tuttle RM, et al. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid. 2001;11(12):1169–1175
  51. Sgouros G, Kolbert KS, Sheikh A, et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. Journal of Nuclear Medicine. 2004;45(8):1366–1372
  52. Jentzen W, Freudenberg L, Eising EG, et al. Optimized 124I PET dosimetry protocol for radio-iodine therapy of differentiated thyroid cancer. Journal of Nuclear Medicine. 2008;49(6):1017–1023
  53. Phan HT, Jager PL, Paans AM, et al. The diagnostic value of 124I-PET in patients with differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2008;35(5):958–965

PII: S1521-690X(08)00119-X

doi: 10.1016/j.beem.2008.10.001

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 6 , Pages 1047-1059 , December 2008

Article Tools

* Image Usage & Resolution